Publications by authors named "Degang Xing"

2 Publications

  • Page 1 of 1

Evaluation of anticancer effects in vitro of new iridium(III) complexes targeting the mitochondria.

J Inorg Biochem 2021 Aug 11;221:111465. Epub 2021 May 11.

School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address:

Iridium(III) complexes have the potential to serve as novel therapeutic drugs for treating tumor. In this work, three new complexes [Ir(ppy)(cdppz)](PF) (1) (ppy = 2-phenylpyridine, cdppz = 11-chlorodipyrido[3,2-a,2',3'-c]phenazine), [Ir(bzq)(cdppz)](PF) (2) (bzq = benzo[h]quinolone) and [Ir(piq)(cdppz)](PF) (3) (piq = 1-phenylisoquinoline) were prepared as well as characterized. MTT (3-(4,5-dimethylthiazole)-2,5-diphenyltetraazolium bromide) assay revealed that the complex 2 exerted potent cytotoxicity against to various cancer cells lines and particularly for SGC-7901 cells. Meanwhile, the complexes could suppress cell colonies formation and migration ability. Apoptosis assays of AO/EB staining as well as flow cytometry revealed that the synthesized complexes may cause apoptosis of SGC-7901 cells. Moreover, the decline of mitochondrial membrane potential (MMP), elevation of intracellular reactive oxygen species (ROS) levels and release of cytochrome c demonstrated the complexes could cause apoptosis mainly through the mitochondrial death pathway and arrest cell at G0/G1 phase. Additionally, the complexes have significant influence on the expression of proteins which is interrelated to cell apoptosis. In summary, our studies provided fundamental information regarding the further study of the possible anticancer mechanisms of iridium (III) complexes.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinorgbio.2021.111465DOI Listing
August 2021

Liposome as drug delivery system enhance anticancer activity of iridium (III) complex.

J Liposome Res 2020 Sep 21:1-14. Epub 2020 Sep 21.

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, PR China.

Herein an Ir(III) complex [Ir(Hppy)(HMNPIP)](PF) (, Hppy = 2-phenylpyridine, HMNPIP = 2-(1-imidazo[4,5-f][1, 10]phenanthroline-3-yl)-6-methoxy-4-nitrophenol) was prepared and characterized. Due to the low anticancer activity of when administered free drug, we prepared a liposome encapsulated form of to improve the antitumor effect, furthermore, we explored the antitumor mechanism of both forms experiments on HepG2 cells. We investigated the inhibitory efficiency of and on cell viability and proliferation using MTT (MTT = 3-(4,5-dimethylthiazole)-2,5-diphenltetraazolium bromide) and colony-forming assay. Intracellular accumulation of reactive oxygen species (ROS) was examined using a fluorescence microscope (High Content Screening System, ImageXpress Micro XLS System, Molecular Devices LLC, Sunnyvale, CA), programmed cell death cells stained with acridine orange/ethidium bromide (AO/EB) using flow cytometry detection and western blot have been performed. An study where HepG2 cells were transplanted into nude nice as xenografts. Tumour volume and body weight were monitored during the 10 days of administration. After encapsulation in liposomes displayed high potency against a variety of tumour cells , especially against HepG2 (IC = 4.6 ± 0.5 μM). Mechanism studies indicated that initiated apoptosis by generating intracellular ROS that regulate lysosomal-mitochondrial dysfunction, followed by microtubule disruption that subsequently leads to a G0/G1 phase of cell cycle arrest. Additionally, significantly curbed tumour growth in nude mice. The tumour inhibitory rate was 51.2% (5.6 mg/kg). Therefore, liposome as a drug delivery system greatly enhances anticancer activity of by a factor of relatively minor side effects.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/08982104.2020.1818779DOI Listing
September 2020